newYou can now listen to Fox News articles!
One tablet may be better than three.
Cardiac medications known as ‘polypills’ reduce the risk of secondary adverse cardiovascular events in individuals who have previously had a heart attack, according to study results presented Friday, August 26, at the European Society of Cardiology (ESC). 2022) in Barcelona, Spain.
Studies have shown a 33% reduction in cardiovascular mortality.
The silent killer hypertension: what is it?
A study published in The New England Journal of Medicine found that the drug, marketed as Trinomia, contains aspirin (100 mg), the angiotensin-converting enzyme inhibitor ramipril (2.5, 5, or 10 mg), and atorvastatin. I know it contains drugs. (20 or 40 mg), according to a news release.
The Spanish National Cardiovascular Research Center (CNIC) and Ferrer developed the polypill.
Polypills are not currently available in the United States.
Valentin Fuster, MD, Director of Mount Sinai Heart, Chief Physician of Mount Sinai Hospital, and General Director of CNIC, led the study.
The results of this study “show for the first time that polypills containing aspirin, ramipril, and atorvastatin clinically adequately reduce the recurrence of cardiovascular events in people who have recovered from a previous heart attack,” he said in a release. Stated.
According to study authors, less than 50% of patients consistently adhere to their medication regimen.
It says, “To better adhere to this simplified approach of using a simple polypill. [pills] Separately as usual,” he continued.
Doctors usually prescribe several drugs after people recover from a heart attack, including antiplatelet drugs (such as aspirin), drugs to control blood pressure, and lipid-lowering drugs such as statins. .
Herbal Supplements and Their Side Effects: Here’s How to Stay Safe
The problem, according to the study authors, is that less than half of patients consistently adhere to their medication regimen.
“Most patients are initially adherent to treatment after an acute event such as an infarction, but adherence declines after the first few months,” Dr. Fuster said in a release.
He added, “Our goal was to make an impact from the beginning. Most patients in the study started taking a simple polypill the first week after having a heart attack.
Dr. José María Castellano, MD, the lead author of the study, said in the report:
Castellano also said in the release: [which is] A very simple strategy that combines the three modalities needed for this type of patient has proven its worth…improved adherence means these patients are receiving better treatment, Low risk of recurrence of cardiovascular events. “
Heart attack risk can be discovered with a non-invasive calcium score screening scan
In a previous study published in the Journal of the American College of Cardiology (JACC), CNIC scientists showed that patients treated with polypills showed significant improvement in adherence to treatment.
A team of researchers at CNIC investigated whether improved adherence to treatment with polypills leads to fewer cardiovascular events.
The study used an international randomized clinical trial of 2,499 patients in seven European countries who had recovered from a heart attack.
Participants were randomly assigned to the CNIC polypill or standard of care. The average age of the participants he was 76 years old, and the study included individuals with hypertension (77.9%), diabetes (57.4%) and a history of smoking (51.3%).
A team of researchers followed patients for an average of three years.
They analyzed the occurrence of four major cardiovascular events: death from cardiovascular causes, non-fatal stroke, non-fatal myocardial infarction, and the need for urgent coronary revascularization, they reported. the book says.
The release found that patients taking the polypill had a 24% lower risk of these four cardiovascular events than those taking the three drugs separately.
Twin sisters help a woman receive emergency medical care on a flight from Boston to Fort Myers, Florida
Researchers found 71 deaths in the group receiving standard care, compared with 48 deaths in the polypill group.
Patients in the polypill group had higher levels of treatment adherence than patients in the control group. This may explain the benefits of the polypill.
“The 33% reduction in cardiovascular mortality demonstrates the efficacy of treatment with Trinomia compared to standard care,” said Oscar Pérez, Ferrer’s head of marketing and business development, in a release. increase.
Polypills could become part of a global treatment strategy.
This therapy has the “potential to reduce the risk of cardiovascular disease recurrence and death worldwide.”
“These results endorse our aim to have a positive impact on society and represent an important step in our mission to provide significant and differentiated value to people suffering from serious health conditions. represents.”
CLICK HERE TO SIGN UP FOR THE LIFESTYLE NEWSLETTER
Polypills could be part of a global treatment strategy to help prevent recurring cardiovascular events in heart attack patients, Fuster said.
Fuster also said that by “simplifying treatment and improving adherence,” this approach “has the potential to reduce the risk of cardiovascular disease recurrence and death globally.”
CLICK HERE TO GET THE FOX NEWS APP
A Mount Sinai Health Systems spokesperson told Fox News Digital that Fuster plans to submit the findings to the U.S. Food and Drug Administration (FDA).